Expiration date: 02/2026

The composition and form of issue: 

Tablets. 1 tablet contains:

chondroitin sulfate (dry 100% basis) 0.25 g

excipient: sufficient amount to obtain a tablet weight of 0.48 g of magnesium carbonate basic water (magnesium carbonate) calcium stearate polyvinylpyrrolidone (povidone) crospovidon MKC 

in a contour acheikova packing 10 PCs. in cardboard pack of 3, 5, 6, 9, or 10 packs.

Description pharmaceutical form:

Tablets from white to yellowish to white with kremovatym color, with inclusions, with valium and chamfer.

Feature:

Acid mucopolysaccharide (sodium salt of chondroitin sulfate) of the cartilage of the trachea of cattle.

Pharmacokinetics:

A single intake of a average therapeutic dose Cmax in plasma achieved through 3-4 h, in the synovial fluid — through 4-5 h.

Accumulates mainly in the cartilage (Cmax in the articular cartilage was achieved after 48 h) synovium is not an obstacle to its penetration into the joint cavity. Excreted by the kidneys within 24 h.

Description pharmacological action:

The symptoms involved in the construction of the basic substance of cartilage and bone tissue affects the exchange processes in hyaline and fibrous cartilage. Hinders the process of degeneration (destruction) of cartilage and connective tissue inhibits the enzymes that cause destruction of cartilage.

Symptoms prevents compression of the connective tissue and plays a role of a lubricant of the articular surfaces. Symptoms stimulates the biosynthesis of glycosaminoglycans, contributes to the regeneration of the joint capsule and cartilage surfaces of the joints, increases the production of synovial fluid. This leads to a reduction of inflammation, increase of mobility of the affected joints and reduce pain at rest and when walking.

The potential to prevent the formation of fibrin clots in synovial and subchondral microcirculatory bed.

Symptoms slows the progression of osteoarthritis and degenerative disc disease, normalizes metabolism in hyaline tissue, stimulates regenerative (rehabilitation) processes in the articular cartilage. In applying the drug hondroksid reduces pain and improves the mobility of affected joints, while the therapeutic effect remains for a long period of time after the end of therapy.

Indications:

Degenerative-dystrophic diseases of joints and spine, including osteoarthritis and osteochondrosis of the spine (treatment and prevention).

Contraindications:

• hypersensitivity to the drug.
  
• pregnancy
  
• the period of breastfeeding.
  

Caution: bleeding and tendency to bleeding.

Application of pregnancy and breast-feeding:

Contraindicated in pregnancy. At the time of treatment should stop breastfeeding.

Side effects:

In rare cases, possible allergic reactions (drug cancel).

Nausea, diarrhea.

Drug interactions:

May increase the action of indirect anticoagulants, antiplatelet agents, fibrinolitikov (in such cases, more frequent monitoring of indicators of blood coagulation).

Method of application and dose:

Inside, squeezed small amounts of water. 0.5 g 2 times a day.

Recommended dosage the initial course is 6 months. The therapeutic effect of the drug is maintained for 3-5 months after its cancellation depending on localization and stage of the disease. If necessary, possibly re courses whose duration is determined individually.